Domain Therapeutics and Explicyte enter immuno-oncology partnership
pharmafile | March 10, 2022 | News story | Business Services |
Domain Therapeutics and Explicyte have announced the signing of a partnership agreement. The two companies aim to combine their expertise to identify GPCR targets and associated biomarkers to discover and develop breakthrough theraueptic programmes for IO.
Explicyte has developed proprietary RNA-sequencing-based data from preclinical syngeneic tumour models, enabling it to interrogate and decipher transcriptomics from the tumour and its microenvironment, and to correlate data to the response to prototypical immune checkpoint inhibitors.
For Domain Therapeutics, these results, cross-validated with clinical RNA-sequencing data, constitute a valuable source of GPCR targets for the development of first-in-class innovative immunotherapies associated with biomarkers.
“We are very happy to enter into a multi-year collaboration with such a long-standing partner,” said Alban Bessede, CEO of Explicyte. “With this partnership, Explicyte will use its expertise to fuel and support Domain’s GPCR-targeting pipeline in IO – a great opportunity for Explicyte to participate in this immunotherapy revolution.”
“Explicyte brings together a panel of expertise that perfectly fits with Domain’s capabilities and IO deployment strategy,” added Xavier Leroy, CSO of Domain Therapeutics. “Having privileged access to -omics data, to discover the next generation of immunotherapies to tackle GPCR-mediated immunoresistance to immune checkpoint inhibitors, has great promise for cancer patients.”
Pascal Neuville, CEO of Domain Therapeutics, added: “Domain’s portfolio is evolving towards a clinical stage pipeline with M1069, an A2a/A2b antagonist currently in Phase 1 and developed by Merck, and our proprietary EP4 antagonist DT-9081, due to enter Phase 1 in S2 2022. This partnership with Explicyte contributes to expanding Domain’s pipeline, with innovative first-in-class programs. It confirms the worldwide and unique positioning of Domain as the GPCR company in IO.”
Lina Adams
